By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Miraculins has launched an early-exercise warrant incentive program intended to encourage the early exercise of up to 7.8 million of its outstanding unlisted warrants.

The Winnipeg, Manitoba-based firm said that the warrants entitle holders to acquire one share of common stock at a price of C$.10 (US$.10) until June 17, 2011. The warrant holders are now being offered an incentive consisting of a half warrant in addition to the common share issuable for each warrant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.